MedWatch

Covid-19 has potentially cost Bavarian Nordic EUR 100m

Covid-19 is still a spanner in the works of Bavarian Nordic's existing vaccine business, as more travel vaccinations have been added to its portfolio. Despite this, CFO Henrik Juuel says this remains the right strategic course for the company.

Photo: PR / Bavarian Nordic

Preparations had been made for the grand transformation of Bavarian Nordic when it acquired the travel vaccines Rabipur and Encepur from Glaxosmithkline in October 2019. Production, however, had barely begun when the Covid-19 pandemic hit.

"It definitely means something for us financially that we haven't gotten the revenue from the vaccines that we had hoped. It's a crossed-out section in the accounts. Across this year and the last, I would estimate that we've lost out on around EUR 100m solely because of Covid-19," EVP and Chief Financial Officer at Bavarian Nordic Henrik Juuel says, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs